AI-Stroke SAS

AI-Stroke operates at the intersection of digital health, medical devices, health diagnostics, and artificial intelligence. Its stated product focus is distinctive in timing: the AI-Stroke Digital Neurologist is intended for pre-hospital or pre-CT assessment rather than solely for image interpretation after a patient reaches a hospital. The platform guides first responders or patients through relevant exercises, captures video, and analyzes those signals to support earlier stroke recognition. The company also emphasizes a stroke-specific clinical and advisory network spanning neurology, neurointervention, radiology, AI, and medical-device quality management. Its $4.6 million seed round and StartX acceptance provide early commercial and clinical credibility, but the company remains a small private venture with limited disclosed evidence of regulatory authorization, hospital adoption, or recurring revenue.

AI-Stroke appears to be moving through an early clinical-commercialization phase. The company was founded in 2022 and remains in the 1–10 employee range, indicating a compact operating base despite an ambitious international healthcare remit. An earlier pre-seed round is listed at €160,000, although a reliable USD equivalent and date are unavailable. The clearest inflection point was the $4.6 million seed round announced on Nov 18, 2025, led by Newfund and involving Bpifrance. That financing materially expanded the resources available for product development, clinical validation, regulatory preparation, and market development. The company’s product is defined as a smartphone-based digital neurologist that analyzes video before CT or MRI, suggesting a launch strategy centered on reducing delays in emergency triage rather than replacing hospital imaging. Acceptance into Stanford StartX on Jan 6, 2026 marks a second inflection point, adding a pathway into U.S. EMS and clinical networks. Simon Jiafeng Li’s appointment as Chief Business Officer supports commercial expansion. Further trajectory will depend on regulatory milestones, prospective validation, EMS deployments, and evidence that earlier assessment improves treatment workflows.